Condition: Thyroid Eye Disease · Sponsor: ACELYRIN Inc.
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Clinical Research Site | Jacksonville, Florida, United States | — |
| Clinical Research Site | Atlanta, Georgia, United States | — |
| Clinical Research Site | Ann Arbor, Michigan, United States | — |
| Clinical Research Site | East Setauket, New York, United States | — |
| Clinical Research Site | New York, New York, United States | — |
| Clinical Research Site | Morgantown, West Virginia, United States | — |
| Clinical Research Site | Sydney, New South Wales, Australia | — |
| Clinical Research Site | Woolloongabba, Queensland, Australia | — |
| Clinical Research Site | Adelaide, South Australia, Australia | — |
| Clinical Research Site | East Melbourne, Victoria, Australia | — |
| Clinical Research Site | Nedlands, Western Australia, Australia | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05683496